ATOS - Atossa Genetics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.20
-0.15 (-4.48%)
At close: 3:59PM EDT

3.20 0.00 (0.00%)
After hours: 4:27PM EDT

Stock chart is not supported by your current browser
Previous Close3.35
Open3.35
Bid3.03 x 1800
Ask3.60 x 900
Day's Range3.16 - 3.37
52 Week Range2.64 - 19.08
Volume70,764
Avg. Volume334,174
Market Cap8.486M
Beta4.24
PE Ratio (TTM)N/A
EPS (TTM)-0.91
Earnings DateAug 13, 2018 - Aug 17, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.00
Trade prices are not sourced from all markets
  • When Should You Buy Atossa Genetics Inc (NASDAQ:ATOS)?
    Simply Wall St.6 hours ago

    When Should You Buy Atossa Genetics Inc (NASDAQ:ATOS)?

    Atossa Genetics Inc (NASDAQ:ATOS), a medical equipment company based in United States, saw a decent share price growth in the teens level on the NasdaqCM over the last few months.Read More...

  • GlobeNewswire9 days ago

    Atossa Genetics Receives Positive Interim Safety Review from Independent Safety Committee in Phase 1 Topical Endoxifen Dose Escalation Study in Men

    Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has received a second positive interim safety review on its Phase 1 study of topical Endoxifen in men, which is being developed to address gynecomastia (or male breast enlargement), a common condition in patients being treated for prostate cancer. Dr. Steven Quay, Ph.D., MD, President and CEO of Atossa commented, "We can now advance to the next level of the study which is to escalate the dosage in the third and final cohort of subjects as we continue to monitor safety and tolerability in the first and second cohorts of the study.

  • GlobeNewswire10 days ago

    Atossa Genetics To Host Corporate Conference Call Wednesday, May 16, 2018 at 4:30pm EDT

    Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced it will host a corporate conference call to discuss the Company’s business on Wednesday, May 16, 2018 at 4:30 EDT. For more information, please visit www.atossagenetics.com.

  • GlobeNewswire10 days ago

    Atossa Genetics Announces First Quarter 2018 Financial Results And Provides Company Update

    SEATTLE, May 14, 2018-- Atossa Genetics Inc., a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced ...

  • GlobeNewswire13 days ago

    Atossa Genetics Supports National Women's Health Week Lead by U.S. Department of Health and Human Services’ Office on Women’s Health

    Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced its support of the 19th Annual National Women’s Health Week lead by the U.S. Department of Health and Human Services’ (HHS) Office on Women’s Health. “As a leading clinical-stage company developing treatment options for breast cancer, we also encourage women to make their health a priority. Managing cardiovascular risks and preventing cancers with screening tests, like the cervical Pap smear and the breast mammogram, are important steps for a long and healthy life,” said Janet R Rea, MSPH, RAC, SVP of Regulatory, Quality and Clinical Affairs for Atossa.

  • GlobeNewswire16 days ago

    Atossa Genetics Regains NASDAQ Compliance

    Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has received notice from NASDAQ that Atossa has regained compliance with NASDAQ minimum closing bid price listing rule 5550(a)(2). Atossa has received notice from NASDAQ stating, in part, that the "Staff has determined that for the last 10 consecutive business days, from April 20 to May 3, the closing bid price of the Company's common stock has been at $1.00 per share or greater.

  • GlobeNewswire17 days ago

    Atossa Genetics Reminds Investors of Today’s Deadline to be a Shareholder of Record

    Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today issued a reminder to shareholders that the record date for its proposed rights offering is May 9, 2018.  To be a shareholder of record, Atossa stock must be purchased by market close on May 7, 2018 to account for two-day settlement. Under the proposed rights offering, Atossa will distribute one non-transferable subscription right for each share of common stock held on the record date.  Each right will entitle the holder to purchase one unit, at a subscription price of $1,000 per unit, consisting of one share of Series B Convertible Preferred Stock with a face value of $1,000 (and immediately convertible into 284 shares of common stock at a conversion price of $3.52 per share) and 284 warrants with an exercise price of $4.05.  The warrants will be exercisable for 4 years after the date of issuance.

  • GlobeNewswire21 days ago

    Atossa Genetics Forms Strategic Advisory Board to Accelerate Growth

    Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced the formation of a strategic advisory board comprised of prominent executives from the pharmaceutical industry. The company has named former Pfizer executive, bestselling author and thought leader, Bob Miglani, and Dr. Joseph M. Chalil, formerly an executive at Boehringer Ingelheim, to the strategic advisory board.

  • ACCESSWIRE23 days ago

    Today’s Research Reports on Stocks to Watch: Atossa Genetics and SteadyMed

    NEW YORK, NY / ACCESSWIRE / May 1, 2018 / Pharma stocks Atossa Genetics and SteadyMed were seeing big gains in Monday trading after each company announced big news. Atossa has received approval from the ...

  • GlobeNewswire24 days ago

    Atossa Genetics Receives Approval from the Swedish Medical Products Agency for Phase 2 Topical Endoxifen Study

    SEATTLE, April 30, 2018-- Atossa Genetics Inc., a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, announced ...

  • ACCESSWIRE28 days ago

    "U.S. Economy Remains Strong, Anticipating Steady Growth with Rate Twist"

    SAN FRANCISCO, CA / ACCESSWIRE / April 26, 2018 / Vista Partners ("Vista") has published April's FREE Macroeconomic & Investment Monthly Newsletter, "U.S. Economy Remains Strong, Anticipating ...

  • GlobeNewswirelast month

    Atossa Genetics Receives Positive Interim Review from Independent Safety Committee in Phase 1 Topical Endoxifen Dose Escalation Study in Men

    Atossa Genetics Inc. (ATOS) (“Atossa” or the “Company”), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has received a positive interim review on its Phase 1 study of topical endoxifen in men, which is being developed to address gynecomastia (or male breast enlargement), which is a common condition in patients being treated for prostate cancer. The Independent Safety Committee reviewed the blinded data generated from the first group in the study (eight subjects) and concluded that the study may advance to the next dosing level. "This positive safety determination is on the critical path for a successful outcome of this Phase 1 study in men," stated Dr. Steven Quay, Ph.D., MD, President and CEO of Atossa.

  • GlobeNewswirelast month

    Atossa Genetics Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering

    SEATTLE, April 23, 2018-- Atossa Genetics Inc., a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today provided ...

  • GlobeNewswirelast month

    Atossa Genetics Announces 1 for 12 Reverse Stock Split

    SEATTLE, April 20, 2018-- Atossa Genetics Inc., a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced ...

  • GlobeNewswirelast month

    Atossa Genetics Requests Shareholders to Vote

    SEATTLE, April 16, 2018-- Atossa Genetics Inc., a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, urges shareholders ...

  • GlobeNewswirelast month

    Report: Developing Opportunities within Ford Motor, Atossa Genetics, Paramount Group, American Airlines Group, Parsley Energy, and eBay — Future Expectations, Projections Moving into 2018

    NEW YORK, April 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • GlobeNewswirelast month

    Atossa Genetics Enrolls First Cohort of Eight Subjects in Endoxifen Study of Male Subjects

    SEATTLE, April 12, 2018-- Atossa Genetics Inc., a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced today ...

  • ACCESSWIRE2 months ago

    "Strong Economic Growth Predicted Despite Volatile Stock Market"

    SAN FRANCISCO, CA / ACCESSWIRE / March 28, 2018 / Vista Partners ("Vista") has published March's FREE Macroeconomic & Investment Monthly Newsletter, " Strong Economic Growth Predicted Despite ...

  • GlobeNewswire2 months ago

    Atossa Genetics Appoints Per Hall, MD, Ph.D. as Scientific Advisor

    SEATTLE, March 27, 2018-- Atossa Genetics Inc., a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions today announced ...

  • GlobeNewswire2 months ago

    Atossa Genetics Launches Mens’ Breast Health Program

    SEATTLE, March 22, 2018-- Atossa Genetics Inc., a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced ...

  • ACCESSWIRE2 months ago

    Atossa Genetics, Endoxifen Progressing, Breast Cancer, Analysts Target and Pipeline Review

    NEW YORK, NY / ACCESSWIRE / March 13, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies, is issuing a comprehensive ...

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Atossa Genetics and Jaguar Health

    NEW YORK, NY / ACCESSWIRE / March 9, 2018 / Shares of Atossa ended in the green on Thursday but fell deep into the red in after-hours trading when it announced its financial report for 2017. Shares of ...

  • GlobeNewswire3 months ago

    Atossa Genetics Announces 2017 Financial Results and Provides Company Update

    SEATTLE, March 08, 2018-- Atossa Genetics Inc., a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announces ...

  • ACCESSWIRE3 months ago

    "Clear Skies Ahead?"

    SAN FRANCISCO, CA / ACCESSWIRE / February 28, 2018 / Vista Partners ("Vista") has published February's FREE Macroeconomic & Investment Monthly Newsletter, "Clear Skies Ahead?" Vista's ...

  • ACCESSWIRE3 months ago

    Atossa Genetic's Janet Rea Presenting On ''TRAP CAR-T and Related Cell Therapies'' at Adoptive T- Cell Therapy Symposium In San Francisco Feb. 15th

    SAN FRANCISCO, CA / ACCESSWIRE / February 14, 2018 / Janet Rea, MSPH, RAC, Senior Vice President of Regulatory, Quality and Clinical Affairs for Atossa Genetics (NASDAQ: ATOS ), a clinical-stage pharmaceutical ...